The rationale of choosing this biomarker as a leading factor for investigation among other candidates is that IL-6 and tumor necrosis factor-alpha (TNF-α) appear to have the highest impact on the promotion of CAD in patients with diabetes mellitus [21]. This evidence concerns the gene IL6 and diabetes mellitus.